The validation of plasma darunavir concentrations determined by the HPLC method for protease inhibitors.
Darunavir (DRV) is a new protease inhibitor used to treat human immunodeficiency virus (HIV) type-1. The aim of this study was to validate the determination of plasma DRV concentrations using the HPLC method, a simple procedure for simultaneous determination of seven HIV protease inhibitors and efavirenz. The calibration curve was linear (range of 0.13 to 10.36 microg/ml). The average accuracy ranged from 100.7 to 105.6%. Both the interday and intraday coefficients of variation were less than 6.7%, which was similar to or much lower than previously reported values by the LC/MS/MS method. It is concluded that HPLC can be used to determine plasma DRV concentrations and routinely in the clinical setting; thus, this HPLC method enables further study of DRV pharmacokinetics in conventional hospital laboratories.
Takahashi
Masaaki
M
Department of Pharmacy, National Hospital Organization Nagoya Medical Center (Tokai Area Central Hospital for AIDS Treatment and Research), Aichi, Japan.
Kudaka
Yuichi
Y
Okumura
Naoya
N
Hirano
Atsushi
A
Banno
Kazuhide
K
Kaneda
Tsuguhiro
T
D000480:Alkynes; D048588:Benzoxazines / Q000097:blood; D002138:Calibration; D002851:Chromatography, High Pressure Liquid; D003521:Cyclopropanes; D000069454:Darunavir; D016903:Drug Monitoring / Q000379:methods; D015658:HIV Infections / Q000097:blood; D017320:HIV Protease Inhibitors / Q000097:blood*; D015497:HIV-1; D006801:Humans; D012015:Reference Standards; D015203:Reproducibility of Results; D012996:Solutions; D013449:Sulfonamides / Q000097:blood*
D000480:Alkynes; D048588:Benzoxazines; D003521:Cyclopropanes; D017320:HIV Protease Inhibitors; D012996:Solutions; D013449:Sulfonamides; C098320:efavirenz; D000069454:Darunavir